Edition:
India

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

7.11USD
19 Jan 2018
Change (% chg)

$-0.24 (-3.27%)
Prev Close
$7.35
Open
$7.34
Day's High
$7.40
Day's Low
$6.89
Volume
2,177,015
Avg. Vol
1,466,623
52-wk High
$14.45
52-wk Low
$5.77

Latest Key Developments (Source: Significant Developments)

Endo International says No Proceedings Have Currently Been Initiated Against EPI As Result Of Subpoena
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO INTERNATIONAL - TO ENDO'S KNOWLEDGE, NO PROCEEDINGS HAVE CURRENTLY BEEN INITIATED AGAINST EPI AS A RESULT OF SUBPOENA - SEC FILING.  Full Article

Endo Comments On U.S. Attorney's Office Grand Jury Subpoena Relating To Products Containing Oxymorphone
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO COMMENTS ON UNITED STATES ATTORNEY'S OFFICE GRAND JURY SUBPOENA RELATING TO PRODUCTS CONTAINING OXYMORPHONE.ENDO INTERNATIONAL - UNIT ENDO PHARMACEUTICALS RECEIVED GRAND JURY SUBPOENA FROM UNITED STATES ATTORNEY'S OFFICE FOR SOUTHERN DISTRICT OF FLORIDA.ENDO - ‍SUBPOENA REQUESTS DISTRIBUTION,THIRD PARTY AGREEMENTS,DOCUMENTS ON INTERACTIONS WITH GOVERNMENT. AGENCIES RELATED TO PRODUCTS CONTAINING OXYMORPHONE​.  Full Article

Glenview Capital Management reports 6.70 pct passive stake in Endo
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Glenview Capital Management Llc::Glenview Capital Management Llc reports 6.70 percent passive stake in Endo International Plc as on October 31, 2017 - SEC filing‍​.  Full Article

Endo posts Q3 adjusted earnings per share $0.91
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Endo International Plc :Endo reports third-quarter 2017 financial results.Q3 adjusted earnings per share $0.91 from continuing operations.Q3 GAAP loss per share $0.45 from continuing operations.Q3 revenue $787 million versus I/B/E/S view $784.9 million.Q3 earnings per share view $0.71 -- Thomson Reuters I/B/E/S.Endo International - ‍for full twelve months ended december 31, 2017, at current exchange rates, Endo is reaffirming its full-year guidance on revenue​.Endo - ‍for full 12 months ended Dec 31, 2017, at current exchange rates, is reaffirming FY guidance on adjusted diluted EPS from continuing operations​.Endo International Plc - ‍during third-quarter 2017, company recorded pre-tax, non-cash asset impairment charges of $95 million​.Endo International Plc - sees FY ‍reported diluted GAAP loss per share from continuing operations to be between $4.94 and $4.64​.FY2017 earnings per share view $3.55, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo sees Q3 ‍revenues of about $785 million​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Endo International Plc :Endo announces certain preliminary financial results for third-quarter 2017 and affirms selected 2017 financial guidance.Sees FY 2017 revenue $3.38 billion to $3.53 billion.Q3 adjusted earnings per share $0.85 from continuing operations.Q3 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Endo International Plc - Sees Q3 ‍revenues of approximately $785 million​.Q3 revenue view $784.9 million -- Thomson Reuters I/B/E/S.FY2016 revenue view $3.92 billion -- Thomson Reuters I/B/E/S.Endo International Plc - ‍Expects 2017 adjusted EPS from continuing operations to be at upper end of guidance ranges of $3.35 to $3.65​.FY2017 earnings per share view $3.52, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.Endo International Plc - Qtrly ‍preliminary​ reported (GAAP) loss per share from continuing operations of about $0.45.Endo - ‍"Unaware" of any unapproved, non-sterile-to-sterile compounding facilities currently selling/distributing Vasopressin injection product​.  Full Article

Endo files federal lawsuit to obtain FDA compliance
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Endo International Plc :Endo files federal lawsuit to obtain FDA compliance with drug quality and security act of 2013.Endo International - ‍lawsuit seeks immediate removal of vasopressin from FDA's Category 1 nominations list.Endo - Units filed suit in court against FDA seeking declaration that FDA's current framework allowing bulk compounding of numerous products is unlawful.Endo - seek removal of vasopressin from FDA's Category 1 nominations list to avoid bulk compounding of vasopressin ‍​by non-sterile-to-sterile outsourcing facilities‍​.  Full Article

Endo International completes divestiture of Grupo Farmacéutico SOMAR
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Endo International PLC :Endo completes divestiture of Grupo Farmacéutico SOMAR.  Full Article

Endo International names Paul Campanelli CEO
Friday, 23 Sep 2016 

Endo International PLC : Endo names Paul Campanelli president and chief executive officer . Company affirms Q3 and full year 2016 financial guidance . Campanelli succeeds Rajiv De Silva, who has stepped down as president, CEO and a member of board . Q3 earnings per share view $0.82, revenue view $864.5 million -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $4.56, revenue view $3.93 billion -- Thomson Reuters I/B/E/S.  Full Article

Vivus says extends return date of Stendra commercial rights
Tuesday, 30 Aug 2016 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Endo International says President and CEO Adopts 10B5-1 trading plan
Friday, 19 Aug 2016 

Endo International Plc : Says CEP Rajiv De Silva has entered into a rule 10b5-1 stock trading plan in connection with his year-end tax planning . Under terms of de silva's stock plan, third-party broker will sell up to 13,500 endo shares owned by de silva . Endo international says de silva's stock being sold, represents about 4 percent of de silva's total endo stock ownership .Says ceo's stock trading plan will be completed in september 2016.  Full Article

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.